BioSpace News Archive

Acorda Therapeutics Chief Technology Officer Rick Batycky is leaving the company to take over the helm of an unnamed biotechnology company.

Gene therapy has been a dream for many researchers for decades—inserting a healthier gene into patients’ cells to replace defective genes and curing diseases. One disease that would seem to be a good target for gene therapy is hemophilia.

As Novartis wrangles with the fallout from its association with Michael Cohen and the fees it paid his consulting company for access to the administration of President Donald Trump, the Swiss pharma giant has brought on a new chief ethics officer.

Shares of Realm Therapeutics have plunged more than 50 percent this morning after the company announced its Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the trial.

Mustang Bio and St. Jude Children’s Research Hospital have signed an exclusive worldwide license deal to develop a first-in-class lentiviral gene therapy for X-linked severe combined immunodeficiency (X-SCID).

Evotec AG and Haplogen GmbH have been long-term collaboration partners. The companies announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases like chronic obstructive pulmonary disease (COPD).

A little more than one year after Flagship Pioneering launched Sigilon Therapeutics, the company has a new chief executive officer. This morning Sigilon announced Bioverativ veteran Rogerio Vivaldi will helm the Cambridge, Mass.-based company.

The industry group PhRMA released its 2018 PhRMA member annual survey along with the 2018 Biopharmaceutical Research Industry Profile. Among the findings was that overall research-and-development spending was at an all-time high in 2017, hitting $71.4 billion, up from $65.5 billion in 2016 and from $29.8 billion in 2001.

Infiniti Research, a global market and customer intelligence solutions provider, has announced the completion of their new market segmentation study on the antibiotic drugs market.

AIVITA Biomedical announced today the initiation of its first clinical site for the Company’s ROOT OF CANCER Phase 2 trial in patients with newly diagnosed glioblastoma (GBM).